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Abstract: 
Introduction: 
Eptifibatide(integrilin)an anti-platelet drug that is a IIb/IIIa glycoprotein inhibitor that prevent 
platelet aggregation and adhesion.one application of integrilin is prevention of acute ischemic 
complications of PCI as the most common method Interventional coronary revascularization but 
reasons which limits its use routinely during PCI was uncomplicated bleeding and high cost of 
conventional dose (bolus dose + infusion). The purpose of this study was to determine the 
therapeutic effect of administration of the bolus dose compared with bolus + infusion of 
integrilin in elective PCI patients. 
Materials and Methods: 
In a this quasi-experimetal trial study that performed in Ardabil University of Medical Sciences, 
Imam Khomeini Hospital on 60 patients undergoing elective PCI were admitted, Patient 
questionnaire was completed then 41 patients based on the absence of contraindications and 
excluded criteria entered study and during PCI integrilin as intracoronarry bolus dose 
prescripted,and follow complications of bleeding and MACE criteria during hospitalization and 
at 1 and 3 months after procedure.and compared with matched control group was administered 
with bolus dose + infusion in the same year and last year and Same center. 
Results: 
46 of patients were male and 14 of them were female. Mean age of without infusion group was 
56.24 ± 10.91 years and patients of with infusion group was 55.89 ± 12.35 years (P=o.293). The 
mean cost of patients in without infusion group was 578000 ± 22270 Rials and in patients of 
with infusion group was 1942100 ± 58050 Rials (P=0.001). In administration bolusdose 
compared to the bolus+infusion significant difference of Bleeding complications (P=0.62), 
ischemia (P=0.62), MI (P=0.767), revascularization (P=0.58) and death (P=0.593) was not 
obtained.MACE criteria in prescription bolus dose have no significantly difference with bolus 
dose + infusion (P=0.48). 
but overall complications (bleeding + ischemia + MI + revascularization + death) was evaluated 
in this study,in group with the infusion was significantly higher than the group without infusion. 
(P=0.047)  
Conclusions: 
The use of intracoronary  bolus dose integrilin of bleeding complications and MACE criteria 
similar  to bolus + infusion and also overall complication and rate cost to the patient is imposed 
less.there for bolus dose can replace safe healthy and effective than conventional dose 
medication.  
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